Drug Trial Radar · NCT04243837
LYT-100 in Patients With BCRL
Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Mar 1, 2020
Primary completion
Sep 9, 2022
Study completion Sep 9, 2022
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jan 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
Conditions
- Breast Cancer Related Lymphoedema
- Lymphoedema
Interventions
LYT-100 BCRLDrug
BCRL patients will receive LYT-100 BID for 6 months
Placebo BCRLDrug
BCRL patients will receive Placebo BID for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: 6 months
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
MACRO Trials
Los Angeles, California
Accel Research Network
Maitland, Florida
Accel Research Network
Atlanta, Georgia
Flinders University
Adelaide, Australia
Macquarie University Health Sciences Centre
Sydney, Australia
University of the Sunshine Coast
Sippy Downs, Queensland, Australia
Ballarat Health Services
Ballarat, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.